American-Israeli biotech Immunai is pursuing the ambitious goal of mapping the immune system and applying machine learning to predict how individual patients will respond to novel and existing drugs.
In the latest In Vivo podcast, Immunai co-founder and chief executive officer Noam Solomon shares his own background, from esteemed academic to young CEO and explains how his company is gathering data from disparate sources to create an atlas of the immune system.
Noam also discusses how he raised $300m, the company’s three acquisitions (unusual for a young biotech), partnerships with big pharma companies like AstraZeneca, artificial biomedical intelligence (ABI) and the many barriers to truly personalized medicine.
Timestamps:
1:00 - Noah’s academic and career trajectory and the founding of Immunai
5:00 -Immunai’s AMICA platform: an atlas of the immune system; and some example applications
9:20 - Partnerships
10:30 - Gleaning insights from AMICA: differences in immune response
14:10 - Raising $300m and making acquisitions to strengthen the platform
18:45 - Hurdles to mapping the immune system
20:00 - Innovation vs. invention
21:50 - What Noam is most excited about in AI in the near-term: artificial biomedical intelligence
23:25 - Barriers to personalized medicine
